

WE CLAIM:

1. A compound of Formula:
YX₁EGTFTSDYSIX₂LDKIAQKAX₃VQWLIAGGPSSGAPPPS;
wherein
X₁ is Aib;
X₂ is Aib;
K at position 20 is chemically modified through conjugation to the
epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-
ethoxy]-acetyl)₂-(γGlu)_a-CO-(CH₂)_b-CO₂H wherein a is 1 to 2 and b is 10
to 20;
X₃ is Phe or 1-Nal;
and the C-terminal amino acid is optionally amidated as a C-terminal
primary amide (SEQ ID NO: 11),
or a pharmaceutically acceptable salt thereof.
2. The compound as claimed in Claim 1, wherein X₃ is Phe.
3. The compound as claimed in Claim 1, wherein X₃ is 1-Nal.
4. The compound as claimed in Claim 2, wherein b is 14 to 18.
5. The compound as claimed in Claim 4, wherein b is 16 to 18.
6. The compound as claimed in Claim 5, wherein b is 18.
7. The compound as claimed in Claim 4, wherein a is 1.
8. The compound as claimed in Claim 4, wherein a is 2.
9. The compound as claimed in Claim 4, wherein the C-terminal amino acid is
amidated as a C-terminal primary amide.
10. The compound as claimed in Claim 1, wherein
X₁ is Aib
X₂ is Aib;
K at position 20 is chemically modified through conjugation to the
epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-
ethoxy]-acetyl)₂-(γGlu)₁-CO-(CH₂)₁₈-CO₂H;
X₃ is Phe;

and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 3),

or a pharmaceutically acceptable salt thereof.

11. The compound as claimed in Claim 1, wherein

X₁ is Aib

X₂ is Aib;

K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γGlu)₂-CO-(CH₂)₁₈-CO₂H;

X₃ is 1-Nal;


and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 4),

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound as claimed in Claim 10 with a pharmaceutically acceptable carrier, diluent, or excipient.

13. The compound as claimed in claim 11 in simultaneous, separate, or sequential combination with an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters.

14. The compound as claimed in Claim 1, wherein the Formula is



15. A pharmaceutical composition comprising the compound as claimed in Claim 14 with a pharmaceutically acceptable carrier, diluent, or excipient.

16. The compound as claimed in claim 14 in simultaneous, separate, or sequential combination with an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters.

Dated this: 29th day of May, 2017



SACHIN BINDAL
OF K & S PARTNERS
AGENT FOR THE APPLICANT(S)
IN/PA-2560

WE CLAIM:

1. A compound of Formula:
 $\text{YX}_1\text{EGTFTSDYSIX}_2\text{LDKIAQKAX}_3\text{VQWLIAGGPSSGAPPPS};$
 wherein
 X_1 is Aib;
 X_2 is Aib;
 K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ Glu)_a-CO-(CH₂)_b-CO₂H wherein a is 1 to 2 and b is 10 to 20;
 X_3 is Phe or 1-Nal;
 and the C-terminal amino acid is optionally amidated as a C-terminal primary amide (SEQ ID NO: 11),
 or a pharmaceutically acceptable salt thereof.
2. The compound [as claimed in](#) Claim 1, wherein X_3 is Phe.
3. The compound [as claimed in](#) Claim 1, wherein X_3 is 1-Nal.
4. The compound [as claimed in](#) Claim 2, wherein b is 14 to 18.
5. The compound [as claimed in](#) Claim 4, wherein b is 16 to 18.
6. The compound [as claimed in](#) Claim 5, wherein b is 18.
7. The compound [as claimed in](#) Claim 4, wherein a is 1.
8. The compound [as claimed in](#) Claim 4, wherein a is 2.
9. The compound [as claimed in](#) Claim 4, wherein the C-terminal amino acid is amidated as a C-terminal primary amide.
10. The compound [as claimed in](#) Claim 1, wherein
 X_1 is Aib
 X_2 is Aib;
 K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ Glu)₁-CO-(CH₂)₁₈-CO₂H;
 X_3 is Phe;

and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 3),

or a pharmaceutically acceptable salt thereof.

11. The compound [as claimed in](#) Claim 1, wherein

X₁ is Aib

X₂ is Aib;

K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γGlu)₂-CO-(CH₂)₁₈-CO₂H;

X₃ is 1-Nal;

and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 4),

or a pharmaceutically acceptable salt thereof.


12. A pharmaceutical composition comprising the compound [as claimed in](#) Claim 10 with a pharmaceutically acceptable carrier, diluent, or excipient.

~~13. The compound of claim 11 for use in therapy.~~

~~14. The compounds of claim 11 for use in the treatment of type 2 diabetes mellitus.~~

~~15.~~ 13. The compound [as claimed in](#) claim 11 in simultaneous, separate, or sequential combination with an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters.

~~16.~~ 14. The compound [as claimed in](#) Claim 1, wherein the Formula is



~~17.~~15. A pharmaceutical composition comprising the compound as claimed in~~ef~~ Claim 14~~6~~ with a pharmaceutically acceptable carrier, diluent, or excipient.

~~18.~~ ~~The compound of claim 16 for use in therapy.~~

~~19.~~ ~~The compounds of claim 16 for use in the treatment of type 2 diabetes mellitus.~~

~~20.~~16. The compound as claimed in~~ef~~ claim 14~~6~~ in simultaneous, separate, or sequential combination with an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters.